Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
34.14 USD | -0.15% | -0.93% | -10.16% |
May. 24 | Inhibrx Shareholders Approve Sale of INBRX-101 Assets to Sanofi | MT |
May. 09 | Inhibrx, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024 | CI |
Business Summary
Number of employees: 169
Sales per Business
USD in Million | 2022 | Weight | 2023 | Weight | Delta |
---|---|---|---|---|---|
Biological Therapeutic Candidates
100.0
%
| 2 | 100.0 % | 2 | 100.0 % | -17.88% |
Sales per region
USD in Million | 2022 | Weight | 2023 | Weight | Delta |
---|---|---|---|---|---|
United States
100.0
%
| 2 | 100.0 % | 2 | 100.0 % | -17.88% |
Managers
Managers | Title | Age | Since |
---|---|---|---|
Brendan Eckelman
FOU | Founder | 45 | 10-03-31 |
Mark Lappe
CEO | Chief Executive Officer | 57 | 10-03-31 |
Kelly Deck
DFI | Director of Finance/CFO | 44 | 18-09-30 |
Robert Boothroyd
CTO | Chief Tech/Sci/R&D Officer | - | 21-12-31 |
Vasily Andrianov
CTO | Chief Tech/Sci/R&D Officer | - | 20-12-31 |
Ashraf Amanullah
CTO | Chief Tech/Sci/R&D Officer | 56 | 18-07-31 |
Jeffrey Jensen
CTO | Chief Tech/Sci/R&D Officer | - | 19-12-31 |
Charbel Helaihel
SAM | Sales & Marketing | - | 23-01-31 |
David Kao
LAW | General Counsel | - | 21-10-27 |
Leah Pollema
LAW | General Counsel | - | 18-12-31 |
Members of the board
Members of the board | Title | Age | Since |
---|---|---|---|
Jon Kayyem
BRD | Director/Board Member | 60 | 18-03-31 |
Mark Lappe
CEO | Chief Executive Officer | 57 | 10-03-31 |
Kimberly Manhard
BRD | Director/Board Member | 64 | 20-05-31 |
Doug Forsyth
BRD | Director/Board Member | 55 | 18-03-31 |
Kristiina Vuori
BRD | Director/Board Member | 56 | 21-10-27 |
Brendan Eckelman
FOU | Founder | 45 | 10-03-31 |
Share class
Vote | Quantity | Free-Float | Company-owned shares | Total Float | |
---|---|---|---|---|---|
Stock A | 1 | 52,401,941 | 38,872,072 ( 74.18 %) | 0 | 74.18 % |
Company contact information
Inhibrx, Inc.
11025 North Torrey Pines Road Suite 200
92037, La Jolla
+858 795 4220
http://www.inhibrx.comSector
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-10.16% | 1.79B | |
+12.30% | 118B | |
+12.15% | 106B | |
-8.14% | 23.4B | |
-0.29% | 22.1B | |
-9.28% | 18.34B | |
-41.70% | 16.59B | |
-15.33% | 15.97B | |
+5.80% | 14.03B | |
+28.03% | 11.67B |
- Stock Market
- Equities
- INBX Stock
- Company Inhibrx, Inc.